Innogenetics, CellTran in talks to combine wound-care activities

By Elaine Rigoli

Tampa, Fla., July 19 - Innogenetics and CellTran jointly announced Wednesday that they have entered into exclusive negotiations toward combining the wound-care activities of CellTran and XCellentis.

CellTran's lead product myskin is based on the use of autologous cell material, or cells derived from a patient's own viable skin cells.

By contrast, Xcellentis' phase 2 candidate LyphoDerm consists of freeze-dried cultured skin cells of allogeneic (donor-derived) origin.

Both companies have also developed technology platforms protected by strong intellectual property positions. For instance, the wound repair-stimulating effects of LyphoDerm are synergized by attractive pharmaceutical properties of the freeze-dried material that include ease of storage, long shelf life and easy application.

For its part, CellTran has developed polymer surface technology for application of autologous skin cells on wound surfaces.

Gent, Belgium-based Innogenetics is an international biopharmaceutical company.

CellTran is a Sheffield, England-based biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.